Introduction
Ferroptosis is an important component in the neurobiology of neurodegenerative [diseases](/diseases). This page provides detailed information about its structure, function, and role in disease processes[@pmid30962574].
Overview
Ferroptosis is a regulated form of non-apoptotic cell death characterized by iron-dependent lipid peroxidation and distinct from [apoptosis](/mechanisms/apoptosis), [necroptosis](/mechanisms/necroptosis), and [@dixon2012]
[autophagy](/mechanisms/autophagy-lysosome-neurodegeneration)-dependent death. First formally described in 2012 by Dixon et al., ferroptosis has rapidly emerged as a critical mechanism of neuronal death in [Alzheimer's disease](/diseases/alzheimers-disease), [@guo2024]
[Parkinson's disease](/diseases/parkinsons-disease), [Huntington's disease](/mechanisms/huntington-pathway), and [ALS](/diseases/amyotrophic-lateral-sclerosis), driven by the brain's unique vulnerability to iron dysregulation and lipid peroxidation[@stockwell2017][@dixon2012]. [@freitas2024]
The brain is particularly susceptible to ferroptosis due to its high iron content (the brain contains ~60 mg of iron in the adult), abundance of polyunsaturated fatty acid (PUFA)-rich membranes (comprising >30% of brain lipids), high oxidative metabolism (consuming ~20% of body oxygen), and limited regenerative capacity. Iron accumulation in specific [brain regions](/brain-regions) is now recognized as a hallmark of multiple neurodegenerative diseases, and ferroptosis represents a mechanistic link between metal dyshomeostasis, [oxidative stress](/mechanisms/oxidative-stress), and neuronal death[@guo2024]. [@zhang2021]
Molecular Mechanism
Core Machinery
Ferroptosis execution requires three converging elements: iron availability, PUFA-containing phospholipids, and failure of antioxidant defense systems. [@thorwald2025]
Iron-dependent lipid peroxidation cascade: [@devos2022]
Iron uptake: Transferrin receptor 1 (TfR1) imports iron-bound transferrin into cells; iron is released in endosomes by acidification and enters the cytosolic labile iron pool (LIP) via DMT1/NRAMP2
Fenton chemistry: Fe²⁺ reacts with H₂O₂ to generate hydroxyl radicals (•OH) via the Fenton reaction: Fe²⁺ + H₂O₂ → Fe³⁺ + •OH + OH⁻
Lipid substrate preparation: ACSL4 esterifies PUFAs (arachidonic acid, adrenic acid) into CoA-derivatives; LPCAT3 incorporates these into membrane phospholipids (particularly phosphatidylethanolamine, PE)
Lipid radical formation: Lipoxygenases (ALOX15, ALOX12) and/or iron-catalyzed Fenton reactions abstract hydrogen atoms from PUFA-PE, generating lipid radicals (L•)
Radical chain propagation: Lipid radicals react with O₂ to form lipid peroxyl radicals (LOO•), which abstract hydrogen from adjacent PUFAs, propagating a self-amplifying chain reaction
Membrane disruption: Accumulation of lipid hydroperoxides (LOOH) alters membrane curvature, generates pores, and ultimately destroys membrane integrity — causing cell deathKey Regulatory Nodes
| Protein/System | Role | Effect on Ferroptosis | [@chen2025]
|---------------|------|----------------------| [@li2025]
| System Xc⁻ (SLC7A11/SLC3A2) | Cystine/glutamate antiporter | Imports cystine for glutathione synthesis; inhibition (by erastin) promotes ferroptosis | [@zhou2025]
| GPX4 | Glutathione peroxidase 4 | Reduces lipid hydroperoxides (LOOH) to alcohols (LOH); the central ferroptosis suppressor | [@meng2024]
| FSP1 (AIFM2) | CoQ10-dependent oxidoreductase | GPX4-independent ferroptosis defense; reduces CoQ10 to CoQ10H₂ which traps lipid radicals | [@li2024]
| DHODH | Dihydroorotate dehydrogenase | Mitochondrial CoQ10 reduction; third anti-ferroptotic pathway | [@deng2024]
| GCH1-BH4 | GTP cyclohydrolase 1 / tetrahydrobiopterin | BH4 acts as radical-trapping antioxidant; fourth independent ferroptosis defense | [@conrad2018]
| Ferritin (FTH1/FTL) | Iron storage | Sequesters labile iron in safe ferric form; ferritinophagy (NCOA4-mediated) releases iron | [@ayton2020]
| ACSL4 | Acyl-CoA synthetase long-chain 4 | Enriches membranes with PUFA-PE; essential for ferroptosis execution | [@yan2019]
| LPCAT3 | Lysophosphatidylcholine acyltransferase 3 | Inserts PUFAs into phospholipids; promotes ferroptosis sensitivity |
| Nrf2 (NFE2L2) | Transcription factor | Master regulator inducing GPX4, SLC7A11, FTH1, HO-1; major ferroptosis suppressor |
| TFRC (TfR1) | Transferrin receptor | Iron uptake; high expression sensitizes cells; recently identified as a ferroptosis marker |
| 7-DHC | 7-Dehydrocholesterol | Endogenous ferroptosis suppressor identified in 2024; traps lipid radicals |
The System Xc⁻–GSH–GPX4 Axis
This is the canonical ferroptosis defense pathway, and its disruption is the most common trigger for ferroptosis:
System Xc⁻ imports extracellular cystine (oxidized cysteine dimer) in exchange for intracellular [glutamate](/entities/glutamate) export (1:1 antiport)
Cystine is reduced to cysteine, the rate-limiting substrate for glutathione (GSH) synthesis (GSH = γ-glutamylcysteinylglycine)
GPX4 uses 2 GSH molecules as cofactors to reduce toxic lipid hydroperoxides (LOOH) to non-toxic lipid alcohols (LOH), oxidizing GSH to GSSG
Disruption at any step — System Xc⁻ inhibition (erastin, sorafenib), GSH depletion (BSO), or GPX4 inactivation (RSL3, FIN56) — triggers ferroptosis
GPX4 is a selenoprotein (contains selenocysteine at its active site), making selenium availability critical for its synthesis and functionParallel Defense Pathways (GPX4-Independent)
Recent discoveries have revealed that cells possess multiple independent ferroptosis defense systems:
- FSP1-CoQ10 axis: FSP1 (formerly AIFM2) localizes to the plasma membrane, where it uses NAD(P)H to reduce CoQ10 to CoQ10H₂, which acts as a lipid radical-trapping antioxidant. This pathway operates completely independently of GPX4
- DHODH-CoQ10 axis: In mitochondria, DHODH generates CoQ10H₂ during pyrimidine synthesis, protecting mitochondrial membranes from ferroptosis
- GCH1-BH4 pathway: GCH1 is the rate-limiting enzyme for tetrahydrobiopterin (BH4) synthesis; BH4 selectively protects PUFA-containing phospholipids from oxidation
- 7-Dehydrocholesterol (7-DHC): Identified in 2024 as a potent endogenous ferroptosis suppressor; 7-DHC scavenges lipid peroxyl radicals through its conjugated diene system, with the resulting oxysterols being non-toxic[@freitas2024]
Ferroptosis in Neurodegenerative Diseases
Alzheimer's Disease
Multiple lines of evidence implicate ferroptosis in AD pathogenesis[@zhang2021][@thorwald2025]:
Iron accumulation:
- Iron is elevated 2-3× in AD-affected [hippocampus](/brain-regions/hippocampus), [cortex](/brain-regions/cortex), and [basal ganglia](/brain-regions/basal-ganglia) relative to age-matched controls
- [amyloid-beta](/proteins/amyloid-beta) plaques concentrate redox-active iron; [Aβ](/proteins/amyloid-beta-protein) peptide binds Fe²⁺/Fe³⁺ at three histidine residues and generates [ROS](/mechanisms/oxidative-stress) through Fenton chemistry
- [Tau](/proteins/tau)(/proteins/tau pathology disrupts iron metabolism; tau]-expressing [neurons](/entities/neurons) show increased labile iron and lipid peroxidation. [Tau](/proteins/tau) facilitates [APP](/entities/app-protein)-mediated iron export; loss of functional [tau](/proteins/tau) impairs this pathway
- Brain iron levels (measured by QSM MRI) correlate with cognitive decline and accelerate [Aβ](/proteins/amyloid-beta-protein) and [tau](/proteins/tau)-mediated neurodegeneration
Lipid peroxidation:
- Elevated 4-hydroxynonenal (4-HNE) and malondialdehyde (MDA) in AD brain tissue, particularly in [hippocampus](/brain-regions/hippocampus) and entorhinal [cortex](/brain-regions/cortex)
- Iron-associated lipid peroxidation is specifically increased in lipid rafts in AD, with decreased expression of ferroptosis suppressors GPX4 and FSP1[@thorwald2025]
- PUFA-rich membranes in AD [hippocampus](/brain-regions/hippocampus) are particularly vulnerable due to high arachidonic acid content
- Isoprostanes (F2-isoprostanes) — non-enzymatic lipid peroxidation products — are elevated in AD CSF and are among the earliest detectable biomarkers
GPX4 dysfunction:
- GPX4 protein expression and activity are reduced in AD hippocampal [neurons](/entities/neurons)
- GSH levels decline progressively from MCI to severe AD
- Selenoprotein synthesis (required for GPX4 active site selenocysteine) is impaired in AD brain
- ACSL4 (the enzyme that sensitizes membranes to ferroptosis) is upregulated in AD brain
Parkinson's Disease
PD has among the strongest evidence for ferroptosis involvement in any neurodegenerative disease:
- [substantia nigra](/brain-regions/substantia-nigra) iron accumulation: [Dopaminergic neurons](/cell-types/dopaminergic-neurons-snpc) in the SNpc have intrinsically high iron content due to iron's role in dopamine synthesis (tyrosine hydroxylase is an iron-dependent enzyme); iron further increases by ~35% in PD
- [dopamine](/entities/dopamine)-iron interaction: Dopamine auto-oxidation generates reactive semiquinones and aminochrome; these react with iron to generate lipid peroxides through Fenton chemistry. Neuromelanin (which normally sequesters iron) releases iron upon neuronal death, creating a feed-forward loop
- GSH depletion: Among the earliest biochemical changes in PD — reduced GSH by ~40% in SNpc precedes detectable neuronal loss and may represent a prodromal biomarker
- Ferroptosis markers: Elevated 4-HNE, MDA, and 8-oxo-dG in PD substantia nigra; decreased GPX4 activity
- [alpha-synuclein](/proteins/alpha-synuclein): Binds iron via C-terminal metal-binding domain and promotes lipid peroxidation; ferroptosis inhibitors (ferrostatin-1, liproxstatin-1) protect against α-synuclein toxicity in cellular and animal models
- FAIRPARK-II trial paradox: The iron chelator deferiprone (15 mg/kg twice daily) reduced brain iron in early PD patients but unexpectedly worsened motor symptoms over 36 weeks in patients not receiving dopaminergic therapy[@devos2022]. This suggests iron may play dual roles — a critical insight for therapeutic development: (a) iron is needed for normal dopamine synthesis, (b) chelation timing relative to disease stage is critical, and (c) concurrent dopaminergic therapy may be necessary
Huntington's Disease
- Striatal iron accumulation: [Medium spiny neurons](/cell-types/medium-spiny-neurons) show progressively increased iron in HD, detectable by QSM MRI before symptom onset
- Mutant [huntingtin](/proteins/huntingtin)/proteins/[huntingtin](/proteins/huntingtin) disrupts iron homeostasis through altered transcription of iron regulatory genes (IRP2, ferritin, ferroportin)
- Ultra-high-field 7T MRI studies correlate cerebral iron levels with neuroinflammatory metabolites in HD, suggesting interconnected ferroptosis and [neuroinflammation](/mechanisms/neuroinflammation) pathways
- Energy deficits from [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction) increase ferroptosis susceptibility by reducing NADPH needed for GPX4/FSP1 recycling
- GPX4 dysfunction may contribute to selective vulnerability of the [striatum](/brain-regions/striatum)
ALS
- Iron accumulation observed in [motor neuron](/cell-types/motor-neurons) [spinal cord](/brain-regions/spinal-cord) segments in [ALS](/diseases/amyotrophic-lateral-sclerosis), particularly in the ventral horn
- GPX4 expression and activity reduced in ALS motor [neurons](/entities/neurons) and patient spinal cord tissue
- Ferroptosis markers (4-HNE, iron) elevated in degenerating motor [neurons](/entities/neurons)
- Mutant SOD1 promotes iron-dependent oxidative damage by losing its normal antioxidant function and gaining pro-oxidant activity
- May act synergistically with [apoptosis](/mechanisms/apoptosis) and [necroptosis](/mechanisms/necroptosis) to drive motor neuron death
- CuATSM (copper-containing compound) shows anti-ferroptotic properties in ALS models and is in [clinical trials](/clinical-trials)
Therapeutic Targeting
Ferroptosis Inhibitors for Neuroprotection
Iron chelators:
| Agent | Route | [BBB](/entities/blood-brain-barrier) Penetration | Clinical Status | Notes |
|-------|-------|----------------|-----------------|-------|
| Deferiprone (DFP) | Oral | Good | Phase II completed (PD); Phase II planned (AD) | FAIRPARK-II: paradoxical worsening in early, untreated PD[@devos2022]; timing and concurrent dopaminergic Rx may be critical |
| Deferoxamine (DFO) | IV/SC | Poor | Preclinical for neurodegeneration | Potent chelator; limited by poor [BBB](/entities/blood-brain-barrier) penetration; intranasal delivery explored |
| Deferasirox | Oral | Moderate | Preclinical | Used clinically for iron overload; neuroprotective in models |
| PBT2 (clioquinol analog) | Oral | Good | Phase II completed (AD, HD) | Metal-protein attenuating compound; modest signal in HD |
Lipophilic radical-trapping antioxidants (RTAs):
- Vitamin E (α-tocopherol): Natural ferroptosis inhibitor; epidemiological evidence of reduced AD risk at high dietary intake; clinical trials (TEAM-AD) showed modest functional benefit in moderate AD
- Ferrostatin-1: Potent synthetic ferroptosis inhibitor; excellent preclinical efficacy in neuronal cultures and brain slices but limited in vivo pharmacokinetics (rapid metabolism)
- Liproxstatin-1: Improved in vivo stability over ferrostatin-1; neuroprotective in GPX4-knockout mice and ischemia models
- 7-Dehydrocholesterol (7-DHC): Endogenous ferroptosis suppressor identified in 2024; potentially targetable by modulating DHCR7 (the enzyme that converts 7-DHC to cholesterol)
- [Edaravone](/therapeutics/edaravone): FDA-approved for ALS; free radical scavenger with anti-ferroptotic properties; may partly explain its modest clinical benefit in ALS
- Idebenone: CoQ10 analog approved for Friedreich's Ataxia; protects against ferroptosis via FSP1-like activity; explored in AD
GPX4 activators and GSH restorers:
- Selenium supplementation: Essential for GPX4 synthesis (selenocysteine at active site); selenium-enriched diets show [neuroprotection](/therapeutics/neuroprotection) in AD and PD models; clinical trials ongoing
- N-acetylcysteine (NAC): GSH precursor; restores intracellular GSH levels; clinical trials in multiple neurological conditions (AD, PD, ALS) with mixed results
- Ebselen: Organoselenium compound with GPX4-mimetic activity; Phase III trials completed for various neurological conditions
[Nrf2](/proteins/nrf2) activators (upstream ferroptosis defense):
- Dimethyl fumarate (DMF): FDA-approved for MS; activates Nrf2, inducing GPX4, SLC7A11, FTH1, and HO-1
- Sulforaphane: Natural Nrf2 activator from cruciferous vegetables; protects against ferroptosis in preclinical models
- Bardoxolone methyl: Potent synthetic Nrf2 activator; renal trials completed; CNS applications being explored
Exercise as Anti-Ferroptosis Therapy
2025 research demonstrates that eight weeks of aerobic exercise significantly activates the System Xc⁻/GPX4 signaling axis in the prefrontal [cortex](/brain-regions/cortex) of AD mice, upregulates ferritin light chain (FTL), downregulates 4-HNE, inhibits ferroptosis, and ameliorates cognitive deficits — providing mechanistic evidence for exercise-mediated neuroprotection against ferroptosis[@chen2025].
Stem Cell-Derived Therapies
Emerging evidence suggests that stem cell derivatives ([exosomes](/entities/exosomes), conditioned media, secretome) from mesenchymal stem cells (MSCs) and neural stem cells can inhibit ferroptosis by restoring GPX4 expression, reducing iron overload, and delivering anti-ferroptotic microRNAs — representing a cell-free therapeutic approach[@li2025].
Key Therapeutic Challenges
- [blood-brain barrier](/entities/blood-brain-barrier): Limited CNS penetration of many ferroptosis-targeting drugs; nanoparticle and antibody shuttle delivery systems are being developed[@zhou2025]
- Iron specificity: Iron chelators (DFO, DFP, DFX) lack tissue and cellular specificity, depleting physiologically essential iron and potentially impairing iron-dependent neurophysiological processes (dopamine synthesis, myelination, mitochondrial respiration)
- Timing paradox: Iron chelation in early PD without dopaminergic support worsened symptoms, suggesting timing relative to disease stage is critical
- Biomarker gap: No ferroptosis-specific biomarkers exist for patient stratification; lipid peroxidation markers (4-HNE, MDA) and iron levels are non-specific
- Pathway redundancy: Blocking ferroptosis may shift cells to [apoptosis](/mechanisms/apoptosis) or [necroptosis](/mechanisms/necroptosis); multi-pathway targeting may be needed
Detection and Biomarkers
Laboratory Methods
| Marker | Method | What It Detects |
|--------|--------|-----------------|
| Lipid peroxidation | C11-BODIPY 581/591, 4-HNE immunostaining, MDA assay, TBARS | Active lipid [ROS](/mechanisms/oxidative-stress) and peroxidation damage products |
| Iron | Prussian blue/Perl's staining, calcein-AM quenching, ICP-MS | Labile and total cellular iron |
| GPX4 | Western blot, immunohistochemistry, activity assay | GPX4 protein levels and enzymatic function |
| GSH/GSSG ratio | ThiolTracker, Ellman's reagent, HPLC | Reduced glutathione levels and redox status |
| Gene signatures | RNA-seq, qPCR panels | PTGS2↑, CHAC1↑, TFRC↑, GPX4↓, SLC7A11↓ |
| Electron microscopy | Transmission EM | Shrunken mitochondria with increased membrane density, reduced cristae (pathognomonic) |
| ACSL4 | Western blot, IHC | PUFA-PE biosynthetic enzyme; ferroptosis sensitivity marker |
Potential Clinical Biomarkers
- Plasma 4-HNE and MDA: Lipid peroxidation markers; elevated in AD, PD, ALS — but not ferroptosis-specific
- CSF iron and ferritin: Direct measures of CNS iron homeostasis; require lumbar puncture
- [Neuroimaging](/diagnostics/neuroimaging) — Quantitative susceptibility mapping (QSM): MRI technique that detects regional iron accumulation in vivo with high sensitivity; iron maps correlate with neurodegeneration severity
- 7T MRI iron mapping: Ultra-high-field MRI enables submillimeter iron mapping; identifies correlations between iron and neuroinflammation in HD
- Isoprostanes (F2-IsoPs): Non-enzymatic lipid peroxidation products in CSF and plasma; among the earliest detectable biomarkers in AD
- Plasma TfR1: Elevated transferrin receptor levels may reflect CNS iron demand; under investigation
Ferroptosis in neuroinflammation
An important emerging concept is the crosstalk between ferroptosis and [neuroinflammation](/mechanisms/neuroinflammation):
- **Iron-loaded [microglia](/entities/microglia) accumulate iron and are susceptible to ferroptosis; ferroptotic [microglia](/cell-types/microglia); can co-occur in the same tissue; Bcl-2 family modulates both (anti-apoptotic Bcl-2 [proteins](/proteins) can suppress ferroptosis via effects on mitochondrial iron)
- [necroptosis](/mechanisms/necroptosis): Both produce necrotic morphology; RIPK1/RIPK3/MLKL drive [necroptosis](/entities/necroptosis) while iron drives ferroptosis; some cross-regulation exists via shared lipid peroxidation pathways
- [autophagy](/mechanisms/autophagy-lysosome-neurodegeneration): Ferritinophagy (NCOA4-mediated autophagic degradation of ferritin) releases sequestered iron into the LIP and promotes ferroptosis; thus excessive [autophagy](/entities/autophagy) can trigger ferroptosis — a critical regulatory link
- [Pyroptosis](/mechanisms/pyroptosis): Gasdermin-mediated pore formation; distinct mechanism but recent evidence suggests gasdermin D cleavage can sensitize to ferroptosis
- Oxeiptosis: Oxygen radical-induced cell death via KEAP1-PGAM5-AIFM1 axis; may converge with ferroptosis under conditions of severe oxidative stress
See Also
- [apoptosis](/mechanisms/apoptosis) — Caspase-dependent programmed cell death
- [necroptosis](/mechanisms/necroptosis) — RIPK-mediated regulated necrosis
- [reactive oxygen species](/mechanisms/oxidative-stress) — Free radical biology
- [blood-brain barrier](/entities/blood-brain-barrier) — Key obstacle for drug delivery
- [microglia](/cell-types/microglia) — Brain immune cells and iron handling
- [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction) — Energy failure in neurodegeneration
- [neuroinflammation](/mechanisms/neuroinflammation) — Inflammatory responses amplifying ferroptosis
External Links
- [FerrDb V2: Ferroptosis Database](http://www.zhounan.org/ferrdb/current/)
- [KEGG: Ferroptosis Pathway](https://www.kegg.jp/pathway/hsa04216)
- [UniProt: GPX4](https://www.uniprot.org/uniprot/P36969)
Background
The study of Ferroptosis has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying [mechanisms of neurodegeneration](/mechanisms) and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Brain Atlas Resources
- Allen Human Brain Atlas: [Ferroptosis expression search](https://human.brain-map.org/microarray/search/show?search_term=Ferroptosis)
- Allen Mouse Brain Atlas: [Ferroptosis search](https://mouse.brain-map.org/search/index.html?query=Ferroptosis)
- Allen Cell Type Atlas: [Transcriptomic cell type reference](https://portal.brain-map.org/atlases-and-data/rnaseq)
- BrainSpan Developmental Transcriptome: [Ferroptosis developmental expression](https://www.brainspan.org/rnaseq/search/index.html?search_term=Ferroptosis)
Pathway Diagram
The following diagram illustrates key molecular interactions and regulatory relationships for Ferroptosis, derived from the SciDEX knowledge graph.
Mermaid diagram (expand to render)
References
[Stockwell BR, et al., Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171(2):273-285. [PubMed (2017)](https://pubmed.ncbi.nlm.nih.gov/29249655/)
[Dixon SJ, et al., Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060-1072. [DOI (2012)](https://doi.org/10.1016/j.cell.2012.03.042)
Guo C, et al., Iron homeostasis and neurodegeneration in the ageing brain: insight into ferroptosis pathways. Ageing Res Rev. 2024;104:102575. [ScienceDirect (2024)
[Freitas FP, et al., 7-Dehydrocholesterol is an endogenous suppressor of ferroptosis. Science. 2024. [DOI (2024)](https://doi.org/10.1126/science.adn7030)
[Zhang Y, et al., The role of ferroptosis in neurodegenerative diseases. Mol Neurobiol. 2021;58(4):1965-1978. [PubMed (2021)](https://pubmed.ncbi.nlm.nih.gov/32832141/)
[Thorwald MA, et al., Iron-associated lipid peroxidation in Alzheimer's Disease is increased in lipid rafts with decreased ferroptosis suppressors, tested by chelation in mice. Alzheimers Dement. 2025. [DOI (2025)](https://doi.org/10.1002/alz.14541)
Devos D, et al., Trial of deferiprone in Parkinson's Disease. N Engl J Med. 2022;387(22):2045-2055. [DOI: 10.1056/NEJMoa2209254 (2022)
[Chen L, et al., Ferroptosis in neurodegenerative diseases: potential mechanisms of exercise intervention. Front Cell Dev Biol. 2025;13:1622544. [DOI (2025)](https://doi.org/10.3389/fcell.2025.1622544)
Li Y, et al., Ferroptosis in neurodegenerative diseases: mechanisms and therapeutic potential of stem cell derivatives. Stem Cell Res Ther. 2025;16:156. [PMC (2025)
Zhou Y, et al., Targeting ferroptosis for neuroprotection: potential therapeutic avenues in neurodegenerative and neuropsychiatric diseases. Front Physiol. 2025;16:1641323. [DOI: 10.3389/fphys.2025.1641323 (2025)
Meng H, et al., Ferroptosis and iron homeostasis: molecular mechanisms and neurodegenerative disease implications. Antioxidants. 2024;14(5):527. [PMC (2024)
[Li J, et al., A critical appraisal of ferroptosis in Alzheimer's and Parkinson's Disease: new insights into emerging mechanisms and therapeutic targets. Front Aging Neurosci. 2024;16:1475934. [PubMed (2024)](https://pubmed.ncbi.nlm.nih.gov/39040474/)
Deng X, et al., The role of ferroptosis in neurodegenerative diseases. Front Cell Neurosci. 2024;18:1475934. [PMC (2024)
Conrad M, et al, Regulation of lipid peroxidation and ferroptosis in diverse species (2018)
Ayton S, et al, Brain iron is associated with accelerated cognitive decline in people with Alzheimer pathology (2020)
Yan N, Zhang JJ, The emerging roles of ferroptosis in vascular cognitive impairment (2019)Pathway Diagram
The following diagram shows the key molecular relationships involving Ferroptosis discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)